BMI range may warrant provider review
29.0
Your number is not the answer. It is the starting line. A licensed provider reviews everything before treatment is recommended.
Start the assessmentPersonalized GLP-1
Body Transformation



Zepbound® is an FDA-approved prescription medication for chronic weight management in adults who meet specific BMI and metabolic health criteria. It contains tirzepatide, a next-generation therapy that activates both GLP-1 and GIP receptors, two key pathways involved in appetite regulation, blood sugar control, and metabolic efficiency.
Zepbound® is an FDA-approved prescription medication for chronic weight management in adults who meet specific BMI and metabolic health criteria. It contains tirzepatide, a next-generation therapy that activates both GLP-1 and GIP receptors, two key pathways involved in appetite regulation, blood sugar control, and metabolic efficiency.
Zepbound® offers a next-generation approach to medical weight management, designed for individuals who need more than appetite suppression alone. Key reasons patients and providers choose Zepbound include:
Dual-hormone action for enhanced results
Zepbound activates both GLP-1 and GIP receptors, addressing appetite regulation, satiety, and metabolic efficiency through two complementary pathways.
FDA-approved for chronic weight management
Clinically evaluated and approved specifically for long-term weight management in adults who meet BMI and health criteria.
Stronger weight-loss potential
Clinical trials demonstrate average total body weight reductions of up to 20% or more, when paired with nutrition and lifestyle changes.
Once-weekly simplicity
Convenient, at-home subcutaneous injections support consistency without daily dosing or in-office visits.
Structured, provider-guided care
Treatment includes personalized dosing, titration, and clinical oversight to support safety, adherence, and sustainable outcomes.
Designed for metabolic alignment
Beyond appetite control, Zepbound supports insulin signaling and metabolic regulation—key drivers of long-term success.
Through Octane Rx, Zepbound is delivered as part of a medically supervised program focused on precision, accountability, and durable progress.
Custom treatment plans designed around your body, goals, and lifestyle.
Dedicated support from licensed providers committed to your success.
Premium healthcare and prescriptions delivered without the waiting room.
Ongoing monitoring and treatment optimization to help you achieve lasting outcomes.
| Feature |
Wegovy® (Semaglutide) |
Most Prescribed
Zepbound® (Tirzepatide)
|
|---|---|---|
| Drug class | GLP-1 agonist | GIP + GLP-1 dual agonist |
| Avg. weight loss | ~15% body weight | ~20–22.5% body weight |
| Dosing schedule | Once weekly | Once weekly |
| Max dose | 2.4 mg | 15 mg |
| FDA approval year | 2021 | 2023 |
| Cardiovascular benefit | ✓ | ✓ |
| Insurance coverage | Broader coverage | Growing coverage |
| Prescription Medication (Paid Only if Approved) | From $149/mo | From $149/mo |
BMI range may warrant provider review
29.0
Your number is not the answer. It is the starting line. A licensed provider reviews everything before treatment is recommended.
Start the assessment
Six calculators. Six protocols.
Complete a quick online assessment, connect with a licensed provider, and receive a customized treatment plan delivered directly to your door.
Zepbound® (tirzepatide) is a once-weekly prescription injection that helps regulate appetite, reduce hunger, and support long-term weight management. It works by activating both GIP and GLP-1 receptors, helping you feel fuller longer and making it easier to maintain healthy lifestyle changes.
Both Wegovy® and Zepbound® are self-administered as a once-weekly subcutaneous injection — meaning a small needle goes just under the skin, typically in the abdomen, thigh, or upper arm.
Each comes in a pre-filled autoinjector pen that makes dosing simple. Your provider will walk you through the technique, and Kin Meds provides detailed injection instructions with your shipment. Doses are gradually increased over the first several months to minimize side effects.
In the SURMOUNT clinical trials, patients on the highest dose lost an average of ~22.5% of body weight, outperforming Wegovy® in head-to-head data. It’s generally considered the more powerful option but may have different insurance coverage and availability depending on your state.
General FDA eligibility guidelines require:
Final eligibility is determined by your licensed provider after reviewing your health intake and lab results. Not all applicants will qualify. Certain medical conditions and medications may be contraindications.
Insurance coverage for branded GLP-1 medications varies significantly by plan. Wegovy® currently has broader insurance coverage than Zepbound®, particularly under plans that cover anti-obesity medications.
Naked Rx operates as a cash-pay program — we provide transparent pricing without relying on insurance approval. However, some patients choose to submit for reimbursement independently through their insurance after receiving their prescription.
The $49 application and screening fee covers the cost of the at-home blood test and clinical intake review — this fee applies regardless of the outcome and is non-refundable as services are rendered during the screening process.
You will not be charged for medication unless a prescription is written and approved. Please review our full Returns & Refund Policy for details.
Naked Rx currently serves patients across most US states. Availability may vary based on state-specific prescribing regulations. During your intake, you’ll be notified if service is not yet available in your state.
Medications are shipped directly to your door in discreet, temperature-controlled packaging by a licensed third-party pharmacy.